MANOLA CUELLAR-HERRERA

Dr. MANOLA CUELLAR-HERRERA

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2020 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
CMChristopher Martínez-Aguirre
Christopher Martínez-Aguirre
FCFrancia Carmona-Cruz
Francia Carmona-Cruz
AVAna Luisa Velasco
Ana Luisa Velasco
FVFrancisco Velasco
Francisco Velasco
GAGustavo Aguado-Carrillo
Gustavo Aguado-Carrillo
LRLuisa Rocha
Luisa Rocha
Experimental evidence indicates that cannabidiol (CBD) induces anxiolytic and antiepileptic effects through the activation of 5-HT1A receptors. These receptors are coupled to Gi/o proteins and induce inhibitory effects. At present, the interaction of CBD with 5-HT1A receptors in the human brain is unknown. The aim of this study focused on evaluating the interaction between CBD and 5-HT1A receptors in cell membranes obtained from the hippocampus and temporal neocortex of autopsies and patients with drug-resistant mesial temporal lobe epilepsy (DR-MTLE). Cell membranes were isolated from the hippocampus and temporal neocortex of a group of patients with DR-MTLE who were submitted to epilepsy surgery (n = 11) and from a group of autopsies (n = 11). The [3H]-8-OH-DPAT binding assay was used to determine the pharmacological interaction of CBD with 5-HT1A receptors. The [35S]-GTPγS assay was used to investigate the CBD-induced activation of Gi/o proteins through its action on 5-HT1A receptors.The CBD affinity (pKi) for 5-HT1A receptors was similar for autopsies and patients with DR-MTLE (hippocampus: 4.29 and 4.47, respectively; temporal neocortex: 4.67 and 4.74, respectively). Concerning the [35S]-GTPγS assay, no statistically significant changes were observed for both hippocampal and neocortical tissue (p > 0.05) at low CBD concentrations (1 pM to 10 μM). In contrast, at high concentrations (100 μM), CBD reduced the constitutive activity of Gi/o proteins of autopsies and DR-MTLE patients (hippocampus: 39.2% and 39.6%, respectively; temporal neocortex: 35.2% and 24.4%, respectively). These changes were partially reversed in the presence of WAY-100635, an antagonist of 5-HT1A receptors, in the autopsy group (hippocampus, 59.8%, p < 0.0001; temporal neocortex, 71.5%, p < 0.0001) and the group of patients with DR-MTLE (hippocampus, 53.7%, p < 0.0001; temporal neocortex, 68.5%, p < 0.001). Our results show that CBD interacts with human 5-HT1A receptors of the hippocampus and temporal neocortex. At low concentrations, the effect of CBD upon Gi/o protein activation is limited. However, at high concentrations, CBD acts as an inverse agonist of 5-HT1A receptors. This effect could modify neuronal excitation and epileptic seizures in patients with DR-MTLE.

Verified
Journal Article
Open access
PDF file
CZCECILIA ZAVALA-TECUAPETLA
CECILIA ZAVALA-TECUAPETLA
MCMANOLA CUELLAR-HERRERA
MANOLA CUELLAR-HERRERA
HLHiram Luna-Munguía
Hiram Luna-Munguía
Epilepsy is a chronic brain disease that affects approximately 65 million people worldwide. However, despite the continuous development of antiepileptic drugs, over 30% patients with epilepsy progress to drug-resistant epilepsy. For this reason, it is a high priority objective in preclinical research to find novel therapeutic targets and to develop effective drugs that prevent or reverse the molecular mechanisms underlying epilepsy progression. Among these potential therapeutic targets, we highlight currently available information involving signaling pathways (Wnt/β-catenin, Mammalian Target of Rapamycin (mTOR) signaling and zinc signaling), enzymes (carbonic anhydrase), proteins (erythropoietin, copine 6 and complement system), channels (Transient Receptor Potential Vanilloid Type 1 (TRPV1) channel) and receptors (galanin and melatonin receptors). All of them have demonstrated a certain degree of efficacy not only in controlling seizures but also in displaying neuroprotective activity and in modifying the progression of epilepsy. Although some research with these specific targets has been done in relation with epilepsy, they have not been fully explored as potential therapeutic targets that could help address the unsolved issue of drug-resistant epilepsy and develop new antiseizure therapies for the treatment of epilepsy.

Verified
Journal Article
Open access
PDF file
CZCECILIA ZAVALA-TECUAPETLA
CECILIA ZAVALA-TECUAPETLA
HLHiram Luna-Munguía
Hiram Luna-Munguía
MLMaría-Leonor López-Meraz
María-Leonor López-Meraz
MCMANOLA CUELLAR-HERRERA
MANOLA CUELLAR-HERRERA
The use of Cannabis for medicinal purposes has been documented since ancient times, where one of its principal cannabinoids extracted from Cannabis sativa, cannabidiol (CBD), has emerged over the last few years as a promising molecule with anti-seizure potential. Here, we present an overview of recent literature pointing out CBD’s pharmacological profile (solubility, metabolism, drug-drug interactions, etc.,), CBD’s interactions with multiple molecular targets as well as advances in preclinical research concerning its anti-seizure effect on both acute seizure models and chronic models of epilepsy. We also highlight the recent attention that has been given to other natural cannabinoids and to synthetic derivatives of CBD as possible compounds with therapeutic anti-seizure potential. All the scientific research reviewed here encourages to continue to investigate the probable therapeutic efficacy of CBD and its related compounds not only in epilepsy but also and specially in drug-resistant epilepsy, since there is a dire need for new and effective drugs to treat this disease.

7 December 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
CMChristopher Martínez-Aguirre
Christopher Martínez-Aguirre
LMLuis Alfredo Márquez
Luis Alfredo Márquez
CCCindy Lizbeth Santiago Castañeda
Cindy Lizbeth Santiago Castañeda
FCFrancia Carmona-Cruz
Francia Carmona-Cruz
MNMaria de los Angeles Nuñez-Lumbreras
Maria de los Angeles Nuñez-Lumbreras
LRLuisa Rocha
Luisa Rocha
Drug-resistant epilepsy (DRE) is associated with high extracellular levels of glutamate. Studies support the idea that cannabidiol (CBD) decreases glutamate over-release. This study focused on investigating whether CBD reduces the evoked glutamate release in cortical synaptic terminals obtained from patients with DRE as well as in a preclinical model of epilepsy. Synaptic terminals (synaptosomes) were obtained from the epileptic neocortex of patients with drug-resistant temporal lobe epilepsy (DR-TLE, n = 10) or drug-resistant extratemporal lobe epilepsy (DR-ETLE, n = 10) submitted to epilepsy surgery. Synaptosomes highly purified by Percoll-sucrose density gradient were characterized by confocal microscopy and Western blot. Synaptosomes were used to estimate the high KCl (33 mM)-evoked glutamate release in the presence of CBD at different concentrations. Our results revealed responsive tissue obtained from seven patients with DR-TLE and seven patients with DR-ETLE. Responsive tissue showed lower glutamate release (p < 0.05) when incubated with CBD at low concentrations (less than 100 µM) but not at higher concentrations. Tissue that was non-responsive to CBD (DR-TLE, n = 3 and DR-ELTE, n = 3) showed high glutamate release despite CBD exposure at different concentrations. Simultaneously, a block of the human epileptic neocortex was used to determine its viability through whole-cell and extracellular electrophysiological recordings. The electrophysiological evaluations supported that the responsive and non-responsive human epileptic neocortices used in the present study exhibited proper neuronal viability and stability to acquire electrophysiological responses. We also investigated whether the subchronic administration of CBD could reduce glutamate over-release in a preclinical model of temporal lobe epilepsy. Administration of CBD (200 mg/kg, p.o. every 24 h for 7 days) to rats with lithium-pilocarpine-evoked spontaneous recurrent seizures reduced glutamate over-release in the hippocampus. The present study revealed that acute exposure to low concentrations of CBD can reduce the glutamate over-release in synaptic terminals obtained from some patients with DRE. This effect is also evident when applied subchronically in rats with spontaneous recurrent seizures. An important finding was the identification of a group of patients that were non-responsive to CBD effects. Future studies are essential to identify biomarkers of responsiveness to CBD to control DRE.


1 October 2018 in Revista Médica del Hospital General de México
Verified
Journal Article
Open access
MCMANOLA CUELLAR-HERRERA
MANOLA CUELLAR-HERRERA
LRL. Rocha
L. Rocha
NSN. Saleh-Subaie
N. Saleh-Subaie
FVF. Velasco
F. Velasco
GAG. Aguado-Carrillo
G. Aguado-Carrillo
AVA.L. Velasco
A.L. Velasco
The 5-hydroxytryptamine-1A receptors are known to be involved in the inhibition of seizures in epilepsy. The main aim of the present study is to determine the functional coupling to G-protein of the 5-HT1A receptor through 8-OH-DPAT-stimulated [35S]GTPγS binding assay in lateral temporal neocortex tissue of patients with mesial temporal lobe epilepsy (mTLE) and correlate it with clinical data. The activation of the G protein complex was determined by [35S]GTPγS binding assay. The temporal neocortex tissue was obtained from 5 patients with mTLE during epilepsy surgery and from 5 subjects (autopsies) who died due to an accident and without history of neurological disease. We found that values of maximal stimulation (Emax) of [35S]GTPγS binding significant decreased in the mTLE group (30.8%, p < .05) when compared to the autopsy samples (65.9%). The values of potency (pEC50) were similar in both groups. However, we found no significant differences between the Emax and age of patient, age of seizure onset, duration of epilepsy and frequency of seizures. Also, the pEC50 values revealed no significant correlations with the clinical data. Our data provide evidence that the lateral temporal neocortex of patients with pharmacoresistant mTLE presents alterations in the functional coupling to G-protein of the 5-HT1A receptor. Such a change could be involved in hyperexcitability in the neocortex of patients with mTLE. Los receptores 5-hidroxitriptamina-1A (5-HT1A) están implicados en la inhibición de las crisis en epilepsia. El presente estudio es determinar el acoplamiento funcional a la proteína-G del receptor 5-HT1A a través del ensayo de unión [35S]GTPγS estimulando al receptor por 8-OH-DPAT (agonista del receptor 5-HT1A) en tejido de neocorteza temporal de pacientes con epilepsia del lóbulo temporal mesial (ELTm) y correlacionar con datos clínicos. La activación del complejo de la proteína G del receptor de mGlu se determinó por [35S]GTPγS por ensayos de unión. Tejido de neocorteza temporal de 5 pacientes con ELTm obtenido de la cirugía de epilepsia y 5 tejidos de autopsias de sujetos que fallecieron por accidente o por causas diferentes a una enfermedad neurológica. Los resultados demostraron estimulación máxima (Emax) significativamente disminuida en el grupo TLEm (30.8%, p < 0,05), en comparación con tejido de muestras de autopsia (65.9%). Los valores de potencia (pEC50) fueron similares en ambos grupos. Sin embargo, no se encontraron diferencias significativas entre la Emax con la edad del paciente, la edad de inicio de las crisis, duración con epilepsia y la frecuencia de crisis. Además, los valores de pEC50 no revelaron correlación con los datos clínicos. Los presente estudio proporcionan evidencia que la neocorteza temporal de pacientes con TLEm fármaco resistente presenta alteraciones en el acoplamiento funcional a la proteína-G del receptor 5-HT1A. Tal cambio podría estar implicado en la hiperexcitabilidad que se observa en la neocorteza de pacientes con ELTm.